ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO458

BMSC-Derived miR-34b-3p Inhibits Peritoneal Fibroblast-to-Myofibroblast Transdifferentiation by Downregulating Spi-C

Session Information

Category: Dialysis

  • 702 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Yu, Fang, Army Medical Center of PLA, Chongqing, Chongqing, China
  • Chen, Kehong, Army Medical Center of PLA, Chongqing, Chongqing, China
  • He, Yani, Army Medical Center of PLA, Chongqing, Chongqing, China

Peritoneal fibrosis is the main reason for the failure of peritoneal dialysis(PD). However, there is no effective intervention. Here, we examined the role and mechanism of bone marrow mesenchymal stem cell-derived exosomes(BMSC-Exos) in regulating the differentiation of fibroblasts (FB) to myofibroblasts (MFB) in peritoneal fibrosis.


C57BL/6 mice were randomly divided into 3 groups:a control group (Saline), a peritoneal injury group (2.5% glucose peritoneal dialysate + LPS), and a peritoneal injury + BMSC-Exos group. The mice were sacrificed and the parietal peritoneum was collected after 6 weeks of modeling. The peritoneum of mice was examined by transcriptomics. The composition and function of BMSC-Exos were analyzed by miRNA sequencing.


Our previous studies have confirmed that exosomes can inhibit peritoneal fibrosis. The expression level of MFB markers increased gradually with the prolongation of the peritoneal fibrosis model. BMSC-Exos treatment significantly decreased the expression of mouse peritoneal MFB markers, suggesting that exosomes can inhibit the differentiation of FB into MFB. Similarly, we further confirmed the effect of BMSC-Exos in vitro. Transcriptomic analysis results revealed that SPIC gene ranked first in the differential expression genes. The mRNA and protein levels of Spi-C were significantly increased in peritoneal injury group, while were significantly down-regulated in BMSC-Exos group. After overexpression of Spi-C in vitro, the differentiation of FB to MFB was significantly increased, and the fibrotic factor (TGF-β1) and TGF-β/WNT pathway(Smad3, β-Catenin) related to FB differentiation was significantly increased, whereas BMSC-Exos intervention could inhibit FB differentiation. miRNA sequencing and bioinformatics analysis showed that miR-34b-3p is one of the main components of BMSC-Exos, and it is the only miRNA that can specifically bind to SPIC gene sequence. In vitro, miR-34b-3p mimics could down-regulate the expression of Spi-C, and the expression of Spi-C was not affected after miR-34b-3p inhibitor intervention.The results suggested that BMSC-Exos-derived miR-34b-3p inhibited the differentiation of FB into MFB by targeting Spi-C.


BMSC-derived miR-34b-3p targeting Spi-C can alleviate peritoneal fibrosis by inhibiting the differentiation of subperitoneal mesothelial FB into MFB.